theirjudgment calls. here you have the breast cancer that you can see. the thing that is white is fat tissue, and the cancer is all this stuff which is kind of purple. so i can see all these details on the slide and check that the quality is good. and once i say, ok, the quality is good, i send it to a server where the ai is performed. and then, after that, i receive a report performed by the ai, telling me what is the relapse risk associated to this slide. and, after that, i can check the report and also see if, for me, the relapse risk is in accordance with what i saw on the microscope. by the nature of it, it needs to collect a lot of data, and that means it s going to take a long time before it can actually
digitising slides isn t a new concept, but running an ai model to determine the risk of cancer returning is. no one involved is suggesting that this will replace the importance of doctors, but the hope is that more detailed data and analysis could enhance theirjudgment calls. here you have the breast cancer that you can see. the thing that is white is fat tissue, and the cancer is all this stuff which is kind of purple. so i can see all these details on the slide and check that the quality is good. and once i say, ok, the quality is good, i send it to a server where the ai is performed. and then, after that, i receive a report performed by the ai, telling me what is the relapse risk associated to this slide. and, after that, i can check the report and also see if, for me, the relapse risk is in accordance
here, you have the breast cancer here, you have the breast cancer that you can see. the thing cancer that you can see. the thing that cancer that you can see. the thing that is why it is fat tissue thing that is why it is fat tissue and the cancer is all this tissue and the cancer is all this stuff tissue and the cancer is all this stuff which is kind of purple this stuff which is kind of purple. i this stuff which is kind of purple. i can see all of these details purple. i can see all of these details on purple. i can see all of these details on the slide and check that the details on the slide and check that the print is good and once jose that the print is good and once jose 0k that the print is good and once jose ok the quality is good, i send jose ok the quality is good, i send it jose ok the quality is good, i send it to jose ok the quality is good, i send it to a server where ai is performed send it to a server where ai is performed and after that, i
the thing that is white is fat tissue, and the cancer is all this stuff which is kind of purple. so i can see all these details on the slide and check that the quality is good. and once i say, ok, the quality is good, i send it to a server where the au is performed. where the ai is performed. and then, after that, i receive a report performed by the ai telling me what is the relapse risk associated to this slide. and, after that, i can check the report and also see if, for me, the relapse risk is in accordance with what i saw on the microscope. by the nature of it, it needs to collect a lot of data, and that means it s going to take a long time before it can actually be properly useful. | i think that a follow up of five j years for the patients included
detailed data and analysis could enhance theirjudgment calls. here you have the breast cancer that you can see. the thing that is white is fat tissue, and the cancer is all this stuff which is kind of purple. so i can see all these details on the slide and check that the quality is good. and once i say, ok, the quality is good, i send it to a server where the ai is performed. and then, after that, i receive a report performed by the ai, telling me what is the relapse risk associated to this slide. and, after that, i can check the report and also see if, for me, the relapse risk is in accordance with what i saw on the microscope. by the nature of it, it needs to collect a lot of data,